PolymarketChiusoVerifica disponibilitàSenza KYC2% di commissioneDati di risoluzione verificatiDiscretamente calibratoQuesto mercato si è risolto: Yes
Risolto: 28 giu 2026, 23:21
Risoluzione verificata dal provider
CoinRithm dispone di prove del provider sul vincitore e sul momento di regolamento di questo mercato.
Esito Vincente
Yes
A 7 giorni
—
A 24 ore
—
Probabilità implicita attuale
Sì 100%+0.0pt
Qualità del mercato
≤49 / 100
Bassa qualitàVolume 24h
4,8K €
Liquidità
—
Liquidità sconosciutaBid / Ask
99.9% / 100.0%
Spread
0.1 pt
Spread strettoVariazione 7g
+26.9 pts
Dati di mercato
Aggiornato 64 giorni fa
Obsoleto4 giu 26, 19:5430 giu 26, 0:00
Cronologia delle Probabilità
No0%
Yes100%
100%
0%
Regole
As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viridian Therapeutics's Veligrotug as a treatment for thyroid eye disease by July 14, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
